Noyes-Whitney Equation and Drug Dissolution Rate

The Noyes-Whitney equation describes how fast a solid dissolves in a surrounding liquid. Published in 1897 by Arthur Noyes and Willis Whitney, it remains the foundational model in pharmaceutical science for predicting and manipulating drug dissolution, which in turn determines how quickly a drug reaches the bloodstream after you swallow a tablet. The equation says that the dissolution rate depends on a handful of physical variables, and understanding those variables gives formulators practical levers for making poorly soluble drugs work better.

What the Equation Actually Says

At its core, the Noyes-Whitney equation states that the rate at which a solid dissolves depends on its solubility in the surrounding liquid, the concentration of dissolved material already present, the diffusion characteristics of the dissolved molecules, and the surface area of the solid exposed to the liquid.¹ In plain terms, a solid dissolves faster when it can dissolve a lot into the liquid (high solubility), when the liquid around it is far from saturated (big concentration gap), when the dissolved molecules move easily through the liquid (high diffusivity), and when there is more solid surface touching the liquid.

The equation is often presented in a modified form credited to Nernst and Brunner, who refined the original model in the early 1900s by introducing the concept of a thin stagnant layer of liquid sitting right at the solid’s surface. Dissolved molecules have to diffuse across this layer before they reach the bulk liquid, so the layer’s thickness acts as a bottleneck. Thicker layer, slower dissolution. This refinement gave scientists a more complete physical picture and made the equation more useful for real-world predictions.

The Concentration Gap Is the Engine

The single most important driver in the equation is the difference between how much drug could dissolve (the saturation solubility) and how much has already dissolved at any given moment. Early on, when the liquid contains almost no dissolved drug, this gap is large and dissolution is fast. As more drug dissolves, the gap shrinks and the process slows. If the liquid becomes saturated, dissolution stops entirely because there is no gap left.

This is why pharmaceutical scientists care so much about “sink conditions” during testing. Sink conditions exist when the saturation solubility in the dissolution medium is at least three times greater than the drug concentration present.² Under sink conditions, the concentration gap stays large throughout the experiment, so the dissolution rate reflects the drug’s intrinsic properties rather than an artifact of the liquid filling up. In the human gut, sink conditions are roughly maintained because dissolved drug is continuously absorbed through the intestinal wall, keeping the local concentration low. Laboratory dissolution tests try to mimic this, though doing so reliably for very poorly soluble drugs can be surprisingly tricky.

Why Particle Size Matters So Much

Surface area is the variable that pharmaceutical formulators have the most direct control over, and the easiest way to increase it is to make particles smaller. Crushing or milling a drug into finer particles exposes more total surface to the dissolving liquid. A single large crystal has relatively little surface for its volume, while the same mass ground into thousands of tiny particles has an enormously greater total surface area.

This relationship is not just theoretical. Studies on poorly water-soluble drugs consistently show that specific surface area increases as particle size decreases, leading to faster dissolution rates.³ Interestingly, the effect is most dramatic during the early stages of dissolution. As the process continues, differences in dissolution rate between particle sizes tend to shrink, because the concentration gap narrows regardless of surface area. So particle size reduction buys you a faster start, which in the body translates to quicker absorption and a faster onset of action.

This principle underlies a large segment of pharmaceutical formulation work. Reducing particles from conventional micron-scale sizes down to the nanometer range can produce striking improvements in dissolution velocity, and experiments with compounds like coenzyme Q₁₀ have confirmed that dissolution speed increases as particle size shrinks, with the magnitude of the effect depending on the diffusion characteristics of the dissolution medium.⁴

The Boundary Layer and What Controls It

The thin layer of liquid right next to a dissolving solid’s surface is central to the Noyes-Whitney framework. Dissolved drug molecules have to diffuse through this stagnant or slow-moving layer before reaching the well-mixed bulk liquid, and the thickness of the layer controls how steep the concentration gradient is. A thinner layer means a steeper gradient and faster dissolution.

Recent modeling work has clarified that there are actually two distinct boundary layers at play under flowing conditions: a hydrodynamic boundary layer that forms because of the fluid flow pattern, and a concentration boundary layer that arises from the dissolved substance and is influenced by flow.⁵ These two layers do not necessarily have the same thickness, and understanding their interplay matters for precise predictions.

Experiments using single-particle dissolution techniques have shown that the effective boundary layer thickness depends on both particle size and the speed of the surrounding fluid. Specifically, the layer grows thicker with larger particles and thinner with faster flow, following a power-law relationship.⁶ This means that stirring or agitation speeds up dissolution not just by moving fresh liquid past the surface, but by physically compressing the boundary layer and steepening the concentration gradient through it.

Nanocrystals and the Solubility Surprise

The Noyes-Whitney equation in its classical form treats saturation solubility as a fixed property of the drug-solvent combination. For particles above a few micrometers, that assumption holds well. But when you shrink particles into the nanometer range, something extra happens: the saturation solubility itself begins to increase. This effect, predicted by the Ostwald-Freundlich equation, occurs because extremely high surface curvature at the nanoscale increases the energy of surface molecules, making them more prone to dissolving.

The practical threshold is generally around one to two micrometers. Below that size, nanocrystals can enhance both the rate and, to a smaller degree, the total extent of dissolution compared to merely micronized material.⁷ Numerical models used in industrial development now routinely combine the Noyes-Whitney and Ostwald-Freundlich equations to predict nanocrystal dissolution behavior in realistic settings.

There is a catch, though. Experimental measurements have found that the actual improvement in initial dissolution rate for nanosized particles is often less than what the Noyes-Whitney equation would predict based on surface area alone.⁸ The reasons are not fully settled, but likely include particle aggregation (nanoparticles tend to clump together, reducing effective surface area), changes in boundary layer behavior at very small scales, and difficulties in measuring true nanoparticle surface area in suspension. This gap between prediction and reality is one of the active frontiers in dissolution science.

Formulation Tricks That Exploit the Equation

Pharmaceutical scientists do not just passively observe the Noyes-Whitney equation; they engineer formulations around it. Each variable in the equation represents a potential intervention point, and the field has developed an extensive toolkit for manipulating them.

Reducing particle size, as covered above, targets surface area. But that is only one lever. Another common approach is to improve wettability, the ability of the dissolution medium to make contact with the drug’s surface. A drug particle that repels water effectively has less functional surface area than a particle of the same size that water spreads across easily. Adding hydrophilic surfactants like poloxamer 407 to formulations improves particle wetting and has been shown to enhance both dissolution rate and oral bioavailability of poorly water-soluble drugs.⁹

Targeting the solubility term directly is another route. Some drugs exist in multiple crystal forms, called polymorphs, and different polymorphs have different solubilities in the same solvent. A less stable polymorph typically dissolves faster and to a higher concentration than the most stable form. Studies on mefenamic acid, for example, found that one polymorph consistently showed higher dissolution rates and saturation concentrations than the other across multiple solvent systems.¹⁰ This is a double-edged sword in drug manufacturing: the fast-dissolving polymorph might improve bioavailability, but it can also be thermodynamically unstable and convert to the slower-dissolving form during storage.

A related strategy is the amorphous solid dispersion, where the drug is embedded in a polymer matrix in a disordered, non-crystalline state. Because amorphous material lacks the regular crystal lattice that has to be broken apart during dissolution, it has a higher apparent solubility and dissolves faster. The tradeoff is stability: amorphous drugs want to recrystallize over time, and keeping them amorphous requires careful polymer selection and processing.

Shrinking particles into the nano range, as discussed, attacks both surface area and, at very small sizes, solubility simultaneously. Reviews of the nanosizing literature emphasize that reducing particle size to the nanometer range increases total surface area and also reduces the boundary layer thickness around each particle, both of which contribute to faster dissolution and improved bioavailability.¹¹

From Lab Flask to Living Gut

The Noyes-Whitney equation was developed for simple systems: a single solid in a well-stirred container of liquid. Inside the human gastrointestinal tract, conditions are far messier. The liquid environment changes constantly as a drug tablet moves from the acidic stomach into the more neutral small intestine. pH shifts alter solubility dramatically, especially for drugs that are weakly acidic or weakly basic. Bile salts and food components in the intestinal fluid can enhance or suppress solubility in ways the equation does not account for on its own.

Research using systems that simulate the stomach-to-intestine fluid transition has shown that how a drug responds to the pH shift during gastric emptying can dominate its dissolution profile. For some drugs, the final dissolved concentration in intestinal fluid is predictable and consistent regardless of formulation details. For others, variations in gastric pH can cause the dissolved concentration to drop by half or more, leading to wide variability in how much drug reaches the bloodstream from one dose to the next.¹² This explains a common clinical frustration: some patients absorb a drug reliably every time they take it, while others see wildly different blood levels from the same pill.

To bridge the gap between bench-top dissolution testing and what happens in a patient, the Biopharmaceutics Classification System (BCS) classifies drugs by their solubility and permeability characteristics. The Noyes-Whitney equation forms the quantitative backbone of the BCS framework, providing the mathematical relationship between a drug’s dissolution rate and the fraction of a dose that actually dissolves in time to be absorbed. When the dose required is small relative to the drug’s solubility in gut fluids, the entire dose dissolves readily and absorption is limited only by permeability. When the dose is large relative to solubility, dissolution becomes the bottleneck and the equation’s variables become critical determinants of bioavailability.¹³

Controlled Release Turns the Equation Inside Out

In immediate-release tablets, the goal is fast dissolution. Controlled-release formulations flip the objective: they use the same physical principles to slow dissolution down. By embedding a drug in a polymer matrix or coating it with a slowly eroding shell, formulators limit how much surface area is exposed at any given time and restrict how quickly the dissolution medium reaches the drug particles.

Modeling these systems requires coupling the Noyes-Whitney equation with diffusion equations and sometimes adsorption terms that account for drug molecules sticking to the matrix material. One approach combines dissolution (described by Noyes-Whitney), diffusion through the swelling tablet, and immobilization of drug molecules by adsorption to tablet components. This combined model has been shown to predict real-world release profiles well, explaining the characteristic slow, sustained drug delivery that controlled-release products are designed to achieve.¹⁴ The Noyes-Whitney equation is doing the same job in both cases: describing the local dissolution event. The difference is that in controlled-release systems, the formulation deliberately constrains the variables that would otherwise drive fast dissolution.

Extensions for Real-World Complexity

The classical Noyes-Whitney equation assumes a single particle size, but real drug powders contain a range of particle sizes. This matters because small particles dissolve faster and disappear first, continuously changing the overall surface area and dissolution rate during the process. Recent modeling work has extended the Noyes-Whitney/Nernst-Brunner framework to handle continuous particle-size distributions rather than assuming a single representative size. This approach retains the underlying distribution throughout the calculation and has demonstrated that results derived under sink conditions can be mathematically reused to predict dissolution under non-sink conditions by applying a time-scaling concept.¹⁵

This is more than an academic exercise. Generic drug approvals rely on dissolution testing to demonstrate equivalence to brand-name products. If the mathematical model does not account for the fact that a powder is a mixture of differently sized particles, it can misjudge how the product will perform. More sophisticated models that work with the actual size distribution provide better predictions and reduce the need for expensive trial-and-error reformulation.

Dissolution Beyond Pills

The Noyes-Whitney framework is not limited to pharmaceuticals. The same physics governs any situation where a solid dissolves in a liquid: limestone dissolving in acidified groundwater, sugar dissolving in coffee, industrial crystals dissolving in process streams. Geochemists studying the dissolution of calcium carbonate minerals in water containing dissolved carbon dioxide, for instance, have found that a diffusion boundary layer at the mineral surface controls dissolution rates much as it does in pharmaceutical systems. However, their work also revealed that under high CO₂ conditions, chemical reaction rates at the surface become the bottleneck rather than diffusion through the boundary layer, a regime the basic Noyes-Whitney model does not capture because it assumes diffusion is always the rate-limiting step.

Environmental scientists use dissolution models to predict how fast mineral deposits will erode in changing ocean chemistry, and food scientists apply similar principles to optimize how quickly flavor crystals or nutrient particles dissolve during processing. The equation’s simplicity and generality are its greatest strengths: a handful of physical variables, each with an intuitive meaning, combined into a relationship that captures the essential behavior of solid dissolution across wildly different contexts. Its limitations, which mostly arise in situations where chemical reactions at the surface or complex fluid dynamics become important, point toward the same kind of boundary-layer refinements that pharmaceutical scientists continue to develop.